The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Modes of resistance to anti-angiogenic therapy
Open accessAbstract
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance, an adaptation to circumvent the specific angiogenic blockade; and intrinsic or pre-existing indifference. Multiple mechanisms can be invoked in different tumour contexts to manifest both evasive and intrinsic resistance, motivating assessment of their prevalence and importance and in turn the design of pharmacological strategies that confer enduring anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This dual blockade approach can provide tumour control in some preclinical models, although the degree of benefit and the underlying mechanism of action seem to be context-dependent31,32,80,89.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [80]
Experimental — accuracy not yet measuredIn the citing paper
“Drug resistance in cancer can be cell-intrinsic (Poulikakos and Rosen, 2011) or a combination of host and tumor mediated pathways (Bergers and Hanahan, 2008; Ebos et al., 2009).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Bergers and Hanahan, 2008
In the citing paper
“Several cellular and molecular mechanisms of escape from antiangiogenic therapies have been postulated and investigated, including activation of alternative angiogenic pathways, recruitment of proangiogenic myeloid cells, increased pericyte cell coverage of tumour blood vessels, increased tumour cell invasion, and alternative modes of vessel recruitment7,9,80”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“Endothelial and pericyte progenitors differentiate into endothelial cells, which form the inner lining of blood vessel walls, or pericytes, the cells that envelop blood vessels, respectivel”
BackgroundPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,551
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,414 · cited 1×
“By contrast, pro-angiogenic monocytes, such as tumour-associated macrophage”
BackgroundVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104 · cited 1×
“aspx?CdrID=39762">paclitaxel extended progression-free survival (but not overall survival”
BackgroundProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“Evidence that low oxygen tension triggers the recruitment of BMDCs stems from observations in experimentally induced ischaemic tissue, wherein endothelial progenitors and other CXCR4 + BMDCs are recruited, in part through increases in HIF1α and its downstream effectors SDF1α (a CXCR4 ligand) and VEGF itsel”
Background
Research works printed but not linked: 1
- Berger, M. S. & Wilson, C. B. The Gliomas (W.B. Saunders, Philadelphia, 1999).
Cited by
Sorted by citations
Items 701–800 of 1,005
Ostapoff, K. T., Awasthi, N., Cenik, B. K., Hinz, S., Dredge, K. S., Schwarz, R. E., & Brekken, R. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1123 · Cited by 67
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
Pinto, M. P., Sotomayor, P. C., Carrasco-Aviño, G., Corvalán, A. H., & Owen, G. I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091489 · Cited by 71
Kuang, R., Jahangiri, A., Mascharak, S., Nguyen, A. T., Chandra, A., Flanigan, P. M., Yagnik, G., Wagner, J. R., Lay, M. D. D., Carrera, D. A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.88815 · Cited by 67
Ragunathrao, V. A. B., Anwar, M., Akhter, M. Z., Chavez, A., Mao, D. Y., Natarajan, V., Lakshmikanthan, S., Chrzanowska‐Wodnicka, M., Dudek, A. Z., Claesson, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.036 · Cited by 68
“The disease reoccurred as these drugs become refractory (Bergers and Hanahan, 2008).”
BackgroundLin, X., Chen, Q., Liu, W., Zhang, J., Wang, S., Lin, Z., & Lin, J.-M. (2015) · Scientific Reports · doi:10.1038/srep09643 · Cited by 67
Wang, L., Li, L., Chen, X., Sun, L., Liao, Y., Huang, N., & Liao, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3416 · Cited by 66
“Antimyeloangiogenic” Therapy for Cancer by Inhibiting PlGF
Loges, S., Schmidt, T., & Carmeliet, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2276 · Cited by 66
“Upon analyzing potential side effects of aPlGF, preclinical studies revealed that unlike VEGF(R)Is, aPlGF (1) does not have teratogenic effects; (2) does not induce hypertension; (3) does not augment the prothrombotic risk factor PAI-1 in the blood plasma; and (4) does neither prune quiescent vessels in the thyroid gl…”
BackgroundMoccia, F. D., Lodola, F., Dragoni, S., Bonetti, E., Bottino, C., Guerra, G., Laforenza, U., Rosti, V., & Tanzi, F. (2014) · Current Vascular Pharmacology · doi:10.2174/157016111201140327162858 · Cited by 64
“Unfortunately, the efficacy of anti-VEGF therapies is short-lived and resistance arises in the majority of patients [62].”
BackgroundYau, T. C. C., Wong, H., Chan, P., Yao, T. J., Pang, R., Cheung, T. T., Fan, S. T., & Poon, R. T. P. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9808-8 · Cited by 66
Wagner, D., Thomssen, C., Haerting, J., & Unverzagt, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008941.pub2 · Cited by 65
Brandes, A. A., Gil‐Gil, M., Saran, F. H., Carpentier, A. F., Nowak, A. K., Mason, W. P., Zagonel, V., Dubois, F., Finocchiaro, G., Fountzilas, G., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0290 · Cited by 66
“between treatment groups (approximately one third) and lower than the proportion of patients using corticosteroids reported at study entry in previous trials of recurrent glioblastoma (49%–54%) [14, 15, 22].”
BackgroundResultRenal Cell Cancer – Insights in Drug Resistance Mechanisms
AWEYS, H., LEWIS, D., Sheriff, M., Rabbani, R. D., Lapitan, P., Sanchez, E., Papadopoulos, V. P., Ghose, A., & Boussios, S. (2023) · Anticancer Research · doi:10.21873/anticanres.16675 · Cited by 71
“These factors induce acquired resistance and therapy failure, primarily by activating the HIF pathway (32).”
BackgroundExtracellular matrix in angiogenesis: dynamic structures with translational potential
Eming, S. A., & Hubbell, J. A. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01309.x · Cited by 67
MicroRNA-mediated regulation of the angiogenic switch
Anand, S., & Cheresh, D. A. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328345a180 · Cited by 67
Integrated PK-PD and agent-based modeling in oncology
Wang, Z., Butner, J. D., Vittorio Cristini, C., & Deisboeck, T. S. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9403-7 · Cited by 69
Contrasting effects of sunitinib within in vivo models of metastasis
Welti, J. C., Powles, T. B., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., van Weverwijk, A., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9291-z · Cited by 66
Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
Kristensen, T., Knutsson, M., Wehland, M., Laursen, B. E., Grimm, D. G., Warnke, E., & Magnusson, N. E. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151223024 · Cited by 68
“Bevacizumab and ramucirumab are monoclonal humanized antibodies designed to inhibit the interaction between VEGF ligands and receptors [25,26], whereas sorafenib is a tyrosine kinase inhibitor (TKI) targeting VEGFRs, but also with an affinity for other tyrosine kinases, including platelet-derived growth factor recepto…”
BackgroundAnti‐angiogenesis and metastasis: a tumour and stromal cell alliance
Moserle, L., & Casanovas, O. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12018 · Cited by 66
Scott, B. J., Lee, E. Q., McNamara, M. B., Ryg, P. A., Batchelor, T. T., & Wen, P. Y. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop073 · Cited by 66
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
Shao, R., Taylor, S. L., Oh, D. S., & Schwartz, L. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5943 · Cited by 69
Deng, C., Zhao, J., Zhou, S., Dong, J., Cao, J., Gao, J., Bai, Y., & Deng, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.010 · Cited by 66
“New blood vessels are required to maintain ongoing exponential growth depending on the type of tumor and its related microenvironment, especially the hypoxic and acidic zones of the microenvironment.(11,12) The irregular shape and diameter of a tumor as well as the unstable pericyte coverage of tumor blood vessels can…”
BackgroundDzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65
“Studies demonstrated that tumor angiogenesis is regulated by several factors and mechanisms and does not solely dependent on VEGF-A signaling (Bergers and Hanahan, 2008; Ferrara, 2016; Potente et al., 2011).”
Zhang, Z., Guo, X. H., Guo, X., Yu, R., Qian, M., Wang, S., Gao, X. C., Qiu, W., Guo, Q., Xu, J., et al. (2021) · Aging · doi:10.18632/aging.202424 · Cited by 65
Reappraising antiangiogenic therapy for breast cancer
Kerbel, R. S. (2011) · The Breast · doi:10.1016/s0960-9776(11)70295-8 · Cited by 65
“By implication, this could also result in the selection and overgrowth of other tumor subpopulations capable of driving and sustaining angiogenesis through the production of alternate growth factors such as bFGF.(35) Indeed, there are now a number of preclinical studies which have indicated that exactly this type of s…”
BackgroundAngiogenesis inhibitors in the treatment of prostate cancer
Hwang, C., & Heath, E. I. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-26 · Cited by 67
“Various mechanisms of resistance to angiogenesis therapy have been outlined [reviewed in [15,20,21]].”
BackgroundEngelmann, D., Mayoli-Nüssle, D., Mayrhofer, C., Fürst, K., Alla, V., Stoll, A., Spitschak, A., Abshagen, K., Vollmar, B., Ran, S., et al. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt035 · Cited by 66
“In line with clinical observations (Bergers and Hanahan, 2008), our results explain how current antiangiogenic treatment rather promotes tumor progression than ameliorates patient survival.”
ResultIn Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 67
“Alternative ways to sustain tumor growth are activated through different mechanisms: up-regulation of alternative pro-angiogenic signaling pathways; recruitment of bone marrow-derived pro-angiogenic cells; increased pericyte coverage of the tumor vasculature; enhancement of invasion and metastasis to provide access to…”
Prokineticins in angiogenesis and cancer
Monnier, J., & Samson, M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.06.011 · Cited by 65
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
de Groot, J., Piao, Y., Tran, H. T., Gilbert, M. R., Wu, H.-K., Liu, J., Bekele, B. N., Cloughesy, T. F., Mehta, M. P., Robins, H. I., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0271 · Cited by 68
“Hypoxia, a pathologic hallmark of glioblastoma, is a known trigger of VEGF, PlGF, and other cytokine production (8, 33) and may be an important mediator of resistance to antiangiogenic therapy (10, 25, 32).”
Angiopoietin-4 Promotes Glioblastoma Progression by Enhancing Tumor Cell Viability and Angiogenesis
Brunckhorst, M. K., Wang, H., Lu, R., & Yu, Q. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4125 · Cited by 66
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 65
Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma
Mooney, J. H., Bernstock, J. D., Ilyas, A., Ibrahim, A. G. A., Yamashita, D., Markert, J. M., & Nakano, I. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.05.205 · Cited by 65
Francesco, E. M. D., Maggiolini, M., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2017) · Oncotarget · doi:10.18632/oncotarget.18445 · Cited by 65
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Solid tumors associated with multiple endocrine neoplasias
Almeida, M. Q., & Stratakis, C. A. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.09.006 · Cited by 64
“However, eventual disease progression during vascular endothelial growth factor receptor inhibitor treatment suggests that the upregulation of other pathways promote tumor growth and metastasis [39].”
Palmieri, V., Lazaris, A., Mayer, T. Z., Petrillo, S. K., Alamri, H., Rada, M., Jarrouj, G., Park, W., Gao, Z., McDonald, P. P., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5449 · Cited by 64
Argentiero, A., Solimando, A. G., Krebs, M., Leone, P., Susca, N., Brunetti, O., Racanelli, V., Vacca, A., & Silvestris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051594 · Cited by 64
“Indeed, the alterations of the HIF/VEGF axis are deemed to be the fundamental target [2], even aiming at overcoming drug resistance [3].”
BackgroundNano-targeting vascular remodeling in cancer: Recent developments and future directions
Giordo, R., Wehbe, Z., Paliogiannis, P., Eid, A. H., Mangoni, A. A., & Pintus, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.001 · Cited by 67
Heidrich, I., Deitert, B., Werner, S., & Pantel, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10075-x · Cited by 65
Fluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies
Rajput, S., Sharma, P. K., & Malviya, R. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100158 · Cited by 67
Biomarkers for Anti-Angiogenic Therapy in Cancer
Wehland, M., Bauer, J. W., Magnusson, N. E., Infanger, M., & Grimm, D. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059338 · Cited by 66
“Moreover, angiogenesis can be induced also via alternative pathways by other soluble factors such as fibroblast growth factor 1 and 2 (FGF1 and FGF2), angiopoietin or ephrin A1 and A2 [13,14].”
BackgroundTherapeutic Targets in Malignant Glioblastoma Microenvironment
Barcellos‐Hoff, M. H., Newcomb, E. W., Zagzag, D., & Narayana, A. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2009.02.004 · Cited by 66
Inspired by Nature: Hydrogels as Versatile Tools for Vascular Engineering
Blache, U., & Ehrbar, M. (2017) · Advances in Wound Care · doi:10.1089/wound.2017.0760 · Cited by 67
Tsioumpekou, M., Cunha, S. I., Ma, H., Åhgren, A., Cedervall, J., Olsson, A., Heldin, C., & Lennartsson, J. (2019) · Theranostics · doi:10.7150/thno.37851 · Cited by 63
“Overactive PDGF signaling has also been reported to be involved in various other tumor types and efforts have been made to target PDGFRs using imatinib, sorafenib or sunitinib among others [25,26].”
BackgroundRetrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
Lu‐Emerson, C., Norden, A. D., Drappatz, J., Lee, E. Q., Beroukhim, R., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Ruland, S. F., & Wen, P. Y. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0489-x · Cited by 62
“As recently reviewed, mechanisms of resistance to antiangiogenic therapies include upregulation of alternative pro-angiogenic signaling pathways; recruitment of proangiogenic bone marrow derived endothelial progenitor cells and monocytes; increase of protective pericyte coverage along tumor vasculature; and activation…”
BackgroundHong, S., Tan, M. H., Wang, S., Luo, S., Chen, Y., & Zhang, L. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1862-5 · Cited by 63
“One possible explanation is that the inhibition of VEGFR kinase activity is quickly compensated by up-regulating alternative pro-angiogenic factors, such as fibroblast growth factor 1 (FGF1) and FGF2, ephrin A1 (Efna1) and Efna2, and angiopoietin 1 (Angpt1) (Bergers and Hanahan 2008).”
BackgroundImproving cancer treatments via dynamical biophysical models
Kuznetsov, M. B., Clairambault, J., & Volpert, V. A. (2021) · Physics of Life Reviews · doi:10.1016/j.plrev.2021.10.001 · Cited by 64
Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
Bohonowych, J. E. S., Gopal, U., & Isaacs, J. S. (2010) · Journal of Oncology · doi:10.1155/2010/412985 · Cited by 64
Dong, Y., Pan, Q., Li, J., Chen, Z., Zhang, F.-F., Liu, Y., Xing, H., Shi, M., Li, J., Li, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.076 · Cited by 63
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
“Extensive reviews have described the transitory nature of the clinical benefit from angiogenesis inhibitors due to evasive resistance and adaptation to circumvent angiogenic blockade (151,152).”
BackgroundTRPV4 channel activation selectively inhibits tumor endothelial cell proliferation
Thoppil, R. J., Adapala, R. K., Cappelli, H. C., Kondeti, V., Dudley, A. C., Gary Meszaros, J., Paruchuri, S., & Thodeti, C. K. (2015) · Scientific Reports · doi:10.1038/srep14257 · Cited by 63
Stalin, J., Nollet, M., Garrigue, P., Fernandez-Sauze, S., Vivancos, L., Essaadi, A., Muller, A., Bachelier, R., Foucault‐Bertaud, A., Fugazza, L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.83 · Cited by 63
Huynh, H. T., Lee, L. Y., Goh, K. Y., Ong, R., Hao, H.-X., Huang, A., Wang, Y., Porta, D. G., Chow, P. K. H., & Chung, A. Y. F. (2018) · Hepatology · doi:10.1002/hep.30481 · Cited by 63
“(16,17) The higher antitumor activity observed in infigratinib-treated mice can plausibly be explained by the ability of infigratinib to inhibit the FGFR pathway and its downstream targets, which are implicated in HCC development, metastasis, and resistance to VEGFR modulating agents.(13,34,35) In high-FGFR-expressing…”
BackgroundResultHashimoto, A., Hashimoto, S., Andõ, R., Noda, K., Ogawa, E., Kotani, H., Hirose, M., Menju, T., Morishige, M., Manabe, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023359 · Cited by 63
“Several angiogenic inhibitors are already in clinical use, including those targeting VEGFs and VEGFR2 [41,42].”
BackgroundZhou, G., Bae, S. D. W., Nguyen, R., Huo, X., Han, S., Zhang, Z., Hebbard, L., Duan, W., Eslam, M., Liddle, C., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.022 · Cited by 62
Wei, Y., Chen, X., Ren, X., Wang, B., Zhang, Q., Bu, H., Qian, J., & Shao, P. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.680369 · Cited by 62
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
Fullmer, T. M., Cabanillas, M. E., & Zafereo, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720723 · Cited by 67
Wireless electrical stimulation at the nanoscale interface induces tumor vascular normalization
Li, C., Xiao, C., Zhan, L., Zhang, Z., Xing, J. Q., Zhai, J., Zhou, Z., Tan, G., Piao, J., Zhou, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.03.027 · Cited by 60
Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis
Eswarappa, S. M., & Fox, P. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3805 · Cited by 62
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Shojaei, F., Simmons, B. H., Lee, J. H., Lappin, P. B., & Christensen, J. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.026 · Cited by 62
The role of epigenetics in age-related macular degeneration
Gemenetzi, M. K., & Lotery, A. J. (2014) · Eye · doi:10.1038/eye.2014.225 · Cited by 63
Yalçın, M., Bharali, D. J., Dyskin, E., Dier, E., Lansing, L., Mousa, S. S., Davis, F. B., Davis, P. J., & Mousa, S. A. (2010) · Thyroid · doi:10.1089/thy.2009.0249 · Cited by 62
“Antiangiogenic agents clinically directed at a specific vascular growth factor have come to be regarded as adjuncts to standard chemotherapy, rather than as primary anticancer modalities (23).”
Croci, D. O., Cerliani, J. P., Pinto, N. A., Morosi, L. G., & Rabinovich, G. A. (2014) · Glycobiology · doi:10.1093/glycob/cwu083 · Cited by 66
“Whereas some tumors are intrinsically refractory to antiangiogenic therapies (intrinsic resistance), in most cases tumors develop adaptive resistance mechanisms to circumvent specific angiogenic blockade (evasive resistance) (Bergers and Hanahan, 2008).”
BackgroundChallenges of drug resistance in the management of pancreatic cancer
Sheikh, R. M., Walsh, N., CLYNES, M. M., O'Connor, R. A., & McDermott, R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.148 · Cited by 61
“describes the modes of resistance to antiangiogenesis drugs by adaptive/evasive resistance [54].”
BackgroundZhang, S., Bu, X., Zhao, H., Yu, J., Wang, Y., Li, D., Zhu, C., Zhu, T., Ren, T., Liu, X., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4311 · Cited by 62
“However, their efficacy is usually transitory, with little benefit to overall survival [3].”
BackgroundOvercoming Resistance to Antiangiogenic Therapies
Tejpar, S., Prenen, H., & Mazzone, M. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0068 · Cited by 62
Delta-Like Ligand 4–Notch Blockade and Tumor Radiation Response
Liu, S. K., Bham, S. A. S., Fokas, E., Beech, J. S., Im, J. H., Cho, S., Harris, A. L., & Muschel, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr419 · Cited by 60
Olson, P., & Hanahan, D. (2009) · Science · doi:10.1126/science.1175940 · Cited by 62
Self-citationBendell, J. C., Gordon, M. S., Hurwitz, H. I., Jones, S. F., Mendelson, D. S., Blobe, G. C., Agarwal, N., Condon, C. H., Wilson, D. M., Pearsall, A. E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1840 · Cited by 63
“treatment due, in part, to induction of other angiogenic pathways (8, 9), and thus there is a need to develop therapeutics directed at novel targets of vascular growth and maturation (4, 10).”
BackgroundChen, Z., Chen, Y., Li, Y., Lian, W., Zheng, K., Zhang, Y., Zhang, Y., Lin, C., Liu, C., Sun, F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03882-7 · Cited by 61
Recent advances in enhancing reactive oxygen species based chemodynamic therapy
Li, X., Luo, R., Liang, X., Wu, Q., & Gong, C. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.11.048 · Cited by 61
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Gerstner, E. R., Ye, X., Duda, D. G., Levine, M. A., Mikkelsen, T., Kaley, T. J., Olson, J. J., Nabors, B., Ahluwalia, M. S., Wen, P. Y., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov085 · Cited by 61
Myeloid-derived suppressor cells: A novel therapeutic target
Ko, J. S., Bukowski, R. M., & Finke, J. H. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0014-6 · Cited by 61
“MDSCs limit antiangiogenic therapy It is now widely accepted that tumor angiogenesis is a crucial step in tumor development [ 17 ].”
BackgroundTaylor, S. M., Nevis, K. R., Park, H. L., Rogers, G. C., Rogers, S. L., Cook, J. G., & Bautch, V. L. (2010) · Blood · doi:10.1182/blood-2010-01-266197 · Cited by 63
Liang, W. P., Kujawski, M., Wu, J., Lu, J., Herrmann, A., Loera, S., Yen, Y., Lee, F., Yu, H., Wen, W. X., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1486 · Cited by 61
“Although the VEGF–VEGF receptor 2 signaling axis is still the most recognized target for antiangiogenic therapy, refactory or progressive resistance to anti-VEGF agents has been widely reported (46, 47).”
BackgroundLee, Y., Karl, D. L., Maduekwe, U. N., Rothrock, C., Ryeom, S. W., D'Amore, P. A., & Yoon, S. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1138 · Cited by 61
RetractedBrauer, M. J., Zhuang, G., Schmidt, M., Yao, J. J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G. A., Chung, A. S., Jubb, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3635 · Cited by 64
“Despite the overall clinical success of bevacizumab and other VEGF pathway inhibitors, clinical efficacy is variable, and some individual patients and tumor types seem to be refractory or to acquire resistance to these therapies (16).”
BackgroundWang, H., Wu, J., Xie, K., Fang, T., Chen, C., Xie, H., Zhou, L., & Zheng, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01938 · Cited by 61
Endothelial Ca2+ Signaling and the Resistance to Anticancer Treatments: Partners in Crime
Moccia, F. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010217 · Cited by 62
The roles and role-players in thyroid cancer angiogenesis
Rajabi, S., Dehghan, M. H., Dastmalchi, R., Mashayekhi, F. J., Salami, S., & Hedayati, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0537 · Cited by 63
Targeting vasa vasorum dysfunction to prevent atherosclerosis
Boyle, E. C., Sedding, D. G., & Haverich, A. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.08.003 · Cited by 60
Guo, R., Chen, Y., Borgard, H., Jijiwa, M., Nasu, M., He, M., & Deng, Y. (2020) · Molecules · doi:10.3390/molecules25204864 · Cited by 63
Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine
Alsaab, H. O., Al-Hibs, A. S., Alzhrani, R. M., Alrabighi, K. K., Alqathama, A. A., Alwithenani, A., Almalki, A. H., & Althobaiti, Y. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041631 · Cited by 62
Qin, W., Xu, W., Wang, L., Ren, D., Cheng, Y., Song, W. W., Jiang, T., Ma, L., & Zhang, C. (2022) · Advanced Science · doi:10.1002/advs.202105086 · Cited by 60
KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation
Jia, Y., Wang, Q., Liang, M., & Huang, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03841-6 · Cited by 65
Xie, W., Xu, H., Hou, Z., Zhang, H., Kong, H., Li, X., & Wang, H. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s55541 · Cited by 60
“50 It is known that tumor invasion and metastasis is a multi-step gradual process with certain procedures, including degradation of ECM, penetration through the vascular endothelial cells, intravascular circulation, and adhesion elsewhere.”
Pathways and targets in hepatocellular carcinoma
Psyrri, A. K., Arkadopoulos, N. F., Vassilakopoulou, M., Smyrniotis, V. E., & Dimitriadis, G. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.113 · Cited by 60
Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting
Westenskow, P. D., Kurihara, T., Aguilar, E., Scheppke, E. L., Moreno, S. K., Wittgrove, C. M., Marchetti, V., Michael, I. P., Anand, S., Nagy, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70230 · Cited by 60
Toaldo, M. B., Salvatore, V., Marinelli, S., Palamà, C., Milazzo, M., Croci, L., Venerandi, L., Cipone, M., Bolondi, L., & Piscaglia, F. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0764-x · Cited by 63
Huang, G., & Chen, L. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0770-6 · Cited by 60
“But the relationship between tumor cells and tumor vasculature is rather complex that tumor itself could utilize many ways to resist angiogenesis inhibitors (Bergers and Hanahan 2008; Shojaei and Ferrara 2008; Ebos et al. 2009; Loges et al. 2009).”
InfluentialRenal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
Bhatt, R. S., Wang, X., Zhang, L., Collins, M. P., Signoretti, S., Alsop, D. C., Goldberg, S. N., Atkins, M. B., & Mier, J. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0477 · Cited by 60
“This acquired “evasive” resistance to VEGF pathway inhibition has been observed in multiple preclinical models and tumor types (7).”
BackgroundIntegration of Repulsive Guidance Cues Generates Avascular Zones That Shape Mammalian Blood Vessels
Meadows, S. M., Fletcher, P. J., Segura, C. M., Xu, K., Neufeld, G., Chauvet, S., Mann, F., Krieg, P. A., & Cleaver, O. B. (2011) · Circulation Research · doi:10.1161/circresaha.111.249847 · Cited by 62
Kickingereder, P., Radbruch, A., Burth, S., Wick, A., Heiland, S., Schlemmer, H.-P., Wick, W., Bendszus, M., & Bonekamp, D. (2015) · Radiology · doi:10.1148/radiol.2015151172 · Cited by 60
Siegal, T., Charbit, H., Paldor, I., Zelikovitch, B., Canello, T., Benis, A., Wong, M. L., Morokoff, A. P., Kaye, A. H., & Lavon, I. (2016) · Journal of neurosurgery · doi:10.3171/2015.8.jns15437 · Cited by 60
Basho, R. K., Yam, C., Gilcrease, M. Z., Murthy, R. K., Helgason, T., Karp, D. D., Meric‐Bernstam, F., Hess, K. R., Valero, V., Albarracin, C. T., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0498 · Cited by 60
“Because bevacizumab was one of the three drugs used in this study, the development of compensatory pathways and resistance in patients previously treated with bevacizumab [34] could arguably be the cause of poorer survival outcomes in nonmetaplastic TNBC.”
BackgroundBrucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231
Xu, M., Wei, P., Suo, M.-Z., Hu, Y., Ding, W., Su, L., Zhu, Y., Song, W.-J., Tang, G.-H., Zhang, M., et al. (2019) · BioMed Research International · doi:10.1155/2019/6543230 · Cited by 60
S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma
Xiao, Y., Zhao, H., Tian, L., Nolley, R., Diep, A. N., Ernst, A., Fuh, K. C., Miao, Y. R., von Eyben, R., Leppert, J. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1366 · Cited by 60
“Mechanisms of angiogenic resistance include activation of compensatory angiogenesis pathways as well as increased tumor invasion (6, 7).”
BackgroundDaum, S., Hagen, H., Naismith, E., Wolf, D. G. F., & Pircher, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.610903 · Cited by 60
“Taking the potent impact of these non-angiogenic processes in cancer progression into consideration, may help us explain the occurring resistance of lung tumors to VEGF-inhibitors (Döme et al., 2007; Bergers and Hanahan, 2008).”
BackgroundFarace, F., Gross‐Goupil, M., Tournay, E., Taylor, M., Vimond, N., Jacques, N., Billiot, F., Mauguen, A., Hill, C., & Escudier, B. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.72 · Cited by 61
“Escape from antiangiogenic therapy has been demonstrated in both pre-clinical and clinical settings (Bergers and Hanahan, 2008).”
BackgroundGururangan, S., Fangusaro, J., Poussaint, T. Y., Onar‐Thomas, A., Gilbertson, R. J., Vajapeyam, S., Gajjar, A. J., Goldman, S., Friedman, H. S., Packer, R. J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos213 · Cited by 59
“Such innate refractoriness to anti-angiogenic therapy does not require a genetic mutation to induce it and occurs despite inhibition of the intended angiogenic target.(27) In the face of angiogenic inhibition, the tumor derives its blood supply through elaboration of additional pro-angiogenic factors, increases pericy…”
Background
Metadata
- Authors
- Bergers, G., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature Reviews Cancer
- Published
- 2008-08
- Volume
- 8
- Issue
- 8
- Pages
- 592-603
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC2874834
- OpenAlex
- W2017322644
- Cited by
- 2,953
- References
- 101
- Citations by year
- 2026: 70 · 2025: 77 · 2024: 97 · 2023: 130 · 2022: 95 · 2021: 172 · 2020: 133 · 2019: 152 · 2018: 148 · 2017: 202 · 2016: 217 · 2015: 228 · 2014: 241 · 2013: 248 · 2012: 215
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA099948)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-angiogenic therapy, drug resistance, vascular endothelial growth factor, VEGF signaling, tumor angiogenesis, intrinsic resistance, combination therapy
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
